论文部分内容阅读
目的:观察东菱克栓酶治疗短暂性脑缺血发作的临床疗效,方法:选择130例短暂性脑缺血发作患者随机分为治疗组和对照组。治疗组在常规药物治疗基础上静脉使用东菱克栓酶20 BU,用法为首日10 BU,以后隔日5 BU 2次,对照组给予口服阿司匹林和复方丹参静滴治疗7 d,1周后及1年后分别评价疗效。结果:治疗组治愈率为81.54%,总有效率92.31%;对照组治愈率为58.46%,总有效率73.85%。两组患者的治愈率及总有效率比较,差异具有显著性意义(P<0.01)。结论:东菱克栓酶治疗短暂性脑缺血发作疗效确切,使用安全且副作用少
Objective: To observe the curative effect of rhubarb thrombin in the treatment of transient ischemic attack. Methods: One hundred and thirty cases of transient ischemic attack were randomly divided into treatment group and control group. Treatment group on the basis of conventional drug treatment of glibenclamide 20 BU, the use of the first day 10 BU, 5 BU 2 times the next day, the control group given oral aspirin and compound Salvia intravenous infusion of 7 d, 1 week and 1 After years of evaluation of efficacy. Results: The cure rate of the treatment group was 81.54%, the total effective rate was 92.31%. The cure rate of the control group was 58.46%, the total effective rate was 73.85%. The two groups of patients with cure rate and total effective rate, the difference was significant (P <0.01). Conclusion: Batroxobin is effective in treating transient ischemic attacks and is safe to use and has few side effects